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AbsTrACT
Objectives idiopathic inflammatory myopathies 
(iiM) are a spectrum of rare autoimmune diseases 
characterised clinically by muscle weakness and 
heterogeneous systemic organ involvement. 
The strongest genetic risk is within the major 
histocompatibility complex (MHc). since autoantibody 
presence defines specific clinical subgroups of iiM, we 
aimed to correlate serotype and genotype, to identify 
novel risk variants in the MHc region that co-occur with 
iiM autoantibodies.
Methods We collected available autoantibody data in 
our cohort of 2582 caucasian patients with iiM. High 
resolution human leucocyte antigen (Hla) alleles and 
corresponding amino acid sequences were imputed using 
snP2Hla from existing genotyping data and tested for 
association with 12 autoantibody subgroups.
results We report associations with eight 
autoantibodies reaching our study-wide significance 
level of p<2.9×10–5. associations with the 8.1 ancestral 
haplotype were found with anti-Jo-1 (Hla-B*08:01, 
p=2.28×10–53 and Hla-DrB1*03:01, p=3.25×10–9), 
anti-PM/scl (Hla-DQB1*02:01, p=1.47×10–26) and anti-
cn1a autoantibodies (Hla-DrB1*03:01, p=1.40×10–11). 
associations independent of this haplotype were found 
with anti-Mi-2 (Hla-DrB1*07:01, p=4.92×10–13) 
and anti-HMGcr autoantibodies (Hla-DrB1*11, 
p=5.09×10–6). amino acid positions may be more 
strongly associated than classical Hla associations; for 
example with anti-Jo-1 autoantibodies and position 74 
of Hla-DrB1 (p=3.47×10–64) and position 9 of Hla-B 
(p=7.03×10–11). We report novel genetic associations 
with Hla-DQB1 anti-TiF1 autoantibodies and identify 
haplotypes that may differ between adult-onset and 
juvenile-onset patients with these autoantibodies.
Conclusions These findings provide new insights 
regarding the functional consequences of genetic 
polymorphisms within the MHc. as autoantibodies in 
iiM correlate with specific clinical features of disease, 
understanding genetic risk underlying development of 
autoantibody profiles has implications for future research.
InTrOduCTIOn
The idiopathic inflammatory myopathies (IIM) are 
a spectrum of rare autoimmune diseases charac-
terised clinically by muscle weakness and systemic 
organ involvement. Clinically, IIM are heteroge-
neous and may be subclassified as dermatomyositis 
(DM), inclusion body myositis (IBM), immune-me-
diated necrotising myopathy, polymyositis (PM) 
and antisynthetase syndrome.1 2
Key messages
What is already known about this subject?
 ► The strongest genetic risk among patients 
with idiopathic inflammatory myopathies (IIM) 
is thought to be within the human leucocyte 
antigen (HLA) region in autoantibody defined 
subgroups.
What does this study add?
 ► This study shows for the first time genetic 
differences between adult-onset and juvenile-
onset patients with anti-TIF1 autoantibodies.
 ► Amino acid imputation identifies novel 
associations with autoantibodies that are 
stronger than classical HLA associations, 
indicating key positions within HLA molecules 
that may confer risk.
How might this impact on clinical practice or 
future developments?
 ► Differing associations in adult and juvenile 
onset disease with the same autoantibody 
suggests distinct aetiologies and disease 
mechanisms.
 ► As autoantibodies in myositis correlate 
with specific clinical features of disease, 
understanding genetic risk underlying 
development of certain autoantibody profiles 
will have implications for future research in IIM.
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Myositis autoantibodies can be detected in approximately 
60%–70% of children and adults with IIM.3 4 Autoantibodies 
unique to IIM are known as myositis-specific autoantibodies 
(MSA), with patients rarely possessing more than one MSA.5 
Autoantibodies that present in patients with myositis in associa-
tion with another connective tissue disease are known as myosi-
tis-associated autoantibodies (MAA).
Clinical classification of IIM can lead to heterogeneous 
subgroups, however, some MSA positive subgroups have specific 
clinical features and may respond differently to treatment. 
Therefore, autoantibody status may be a more meaningful way 
to characterise patients to understand pathogenesis and predict 
prognosis.3 For example, patients with anti-histidyl–tRNA-syn-
thetase (anti-Jo-1) commonly present with myositis, Raynaud’s 
phenomenon, polyarthritis and a high frequency of interstitial 
lung disease.6 Patients with autoantibodies directed against anti-
Mi-2 present with hallmark cutaneous manifestations of DM, 
generally milder myositis and a favourable response to immuno-
suppressive treatment.7
IIM are thought to be complex genetic diseases, initiated by 
immune activation following specific environmental events in 
genetically predisposed individuals. The major histocompat-
ibility complex (MHC), also known as the human leucocyte 
antigen (HLA) region, has consistently been identified as the 
strongest risk factor for IIM and clinical subgroups.8 Studies 
have shown that the strongest HLA associations among 
patients with IIM are found when stratifying by autoanti-
body status.9–11 In particular, the strongest risk is with the 8.1 
ancestral haplotype (8.1 AH), a common haplotype of exten-
sive linkage disequilibrium (LD) in Caucasian populations that 
confers susceptibility to IIM and many other autoimmune or 
immune-mediated diseases.12 Associations with alleles inde-
pendent of the 8.1 AH have also been reported.9 New MSAs 
and MAAs have since been discovered, and small studies have 
identified potential HLA associations with these autoantibodies, 
for example, HLA-DRB1*11:01 in patients with anti-3-hy-
droxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) 
autoantibodies in adult-onset disease.13
Here, we aimed to correlate serotype with genotype in patients 
with IIM, with sufficient statistical power, to identify novel risk 
variants in the MHC region that confer susceptibility to IIM 
autoantibodies and to provide a definitive replication cohort for 
previously reported associations.
MeTHOds
study population
Through the Myositis Genetics Consortium (MYOGEN), 2582 
Caucasian cases from 14 countries were recruited (online supple-
mentary table 1).8 Written informed consent was obtained from 
all patients with approval from research ethics committees of 
institutional review boards at each participating centre. Patients 
were enrolled in to MYOGEN if they fulfilled Bohan and Peter 
criteria for PM and adult and juvenile DM,8 or Griggs, Medical 
Research Council (MRC) or European Neuromuscular Centre 
(ENMC) criteria for patients with IBM.14 Shared control geno-
types were drawn from a pool of 15 651 individuals from 12 
countries as described previously.8 Genotypes from an additional 
19 UK juvenile-onset patients were included from the Juvenile 
Dermatomyositis Cohort Biomarker Study and Repository. 
Patients were classified as having juvenile IIM if age of onset 
was <16 years old, except in the USA, where 18 years old was 
considered the cut-off.
Autoantibody testing
Myositis relevant autoantibodies were detected using immu-
noprecipitation (IP), line blot or ELISA, as detailed in online 
supplementary table 2. Further details are described in online 
supplementary method.
Genotyping
Genotyping was performed in accordance with UK-based and 
US-based Illumina protocols (Centre for Genetics and Genomics 
Arthritis Research UK, University of Manchester; Feinstein 
Institute, New York; University College London, London, UK). 
Standard quality control (QC) was performed as described 
previously.8
HLA imputation
Classical HLA alleles and corresponding amino acid sequences 
were imputed using SNP2HLA with reference data collected by 
the Type 1 Diabetes Genetics Consortium.15 Cases and controls 
were imputed together. Postimputation QC removed variants 
with a minor allele frequency <0.01 and variants with an infor-
mation score <0.8.
statistical analysis
We employed a case-control study design in each autoanti-
body subgroup analysis. Controls were matched for ethnicity 
using principal components analysis (PCA), due to absence of 
geographically matched controls for each IIM cohort. Four 
healthy controls for each case were matched for ethnicity using 
(PCA) coordinates, using a method described previously.16 
Analysis was performed in R (V.3.1.0) on the dosage of vari-
ants (genotype probabilities) which takes into account imputa-
tion uncertainty. Single-test association was performed for HLA 
alleles and omnibus tests for multiallelic sites. For multiallelic 
sites, such as amino acids, we identified the most common 
residue or allele in the control population to be selected as the 
reference. A logistic regression assuming an additive model was 
used to test for association, with gender and the top 10 principal 
components included as covariates. Forward stepwise logistic 
regression was used to test for independent effects conditional on 
the variant of interest. ORs ratios were generated with multivar-
iate logistic regression. Significance was defined as p<2.9×10–5 
based on a Bonferroni correction of the pre-QC 1700 variants 
imputed by SNP2HLA.
resuLTs
Autoantibody frequencies in the study population
Genetic data were available for 2582 patients with IIM, the 
majority of whom were tested for at least one autoantibody. 
The number of autoantibody positive cases present in the cohort 
is shown in table 1, for groups where n>10. Autoantibody 
frequencies are as a proportion of those in tested individuals and 
do not necessarily represent the prevalence of autoantibodies in 
an IIM population.
strong classical HLA associations are observed in IIM 
autoantibody subgroups
Data quality was evaluated after imputation by determining the 
concordance between imputed alleles and existing HLA typing 
from next generation sequencing technology (HistoGenetics, 
New York, USA) for 162 individuals. There was a high level 
of concordance across all loci for both 2-digit (96.6%–100%) 
and 4-digit (94.8%–100%) alleles (online supplementary table 
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Table 1 Number of patients with myositis with myositis-specific or associated autoantibodies
Antibody
Adult-onset IIM Juvenile-onset IIM Total number 
positive
(Adult+juvenile-
onset)number tested number antibody positive number tested number antibody positive
Jo-1 1937 325 (16.8%) 447 7 (1.6%) 332
TIF1 1697 91 (5.4%) 356 106 (29.8%) 197
PM/Scl 1883 120 (6.4%) 457 16 (3.5%) 136
Mi-2 1884 87 (4.6%) 456 17 (3.7%) 104
NXP2 1502 28 (1.9%) 360 65 (18.1%) 93
cN1A 232 46 (19.8%) 81 18 (22.2%) 64
SRP 1822 45 (2.5%) 457 0 45
HMGCR 1264 51 (4.0%) 130 1 (0.8%) 52
MDA5 1674 18 (1.1%) 402 17 (4.2%) 35
SAE 1518 31 (2.0%) 397 0 31
PL7 1927 23 (1.2%) 457 0 23
PL12 1927 11 (0.6%) 457 0 11
Myositis-specific/associated autoantibodies n>10 in cohort, stratified by adult-onset and juvenile-onset disease. Frequency is of those patients tested for each autoantibody 
within the cohort, where testing was not necessarily random.
IIM, idiopathic inflammatory myopathies.
Table 2 Classical HLA allele associations
Autoantibody number of cases
snP2HLA classical HLA association
Gene Allele P value Or (95% CI)
Jo-1 332 HLA-B 08:01 2.28×10–53 3.37 (2.37 to 4.83)
HLA-DRB1 03:01 3.25×10–9 3.09 (2.08 to 4.30)
TIF1 197 HLA-DQB1 02 2.34×10–10 2.49 (1.88 to 3.31)
PM/Scl 136 HLA-DQB1 02:01 1.47×10–26 17.50 (10.63 to 30.59)
Mi-2 104 HLA-DRB1 07:01 4.92×10–13 5.47 (3.48 to 8.77)
cN1A 64 HLA-DRB1 03:01 1.40×10–11 9.23 (4.95 to 18.01)
HMGCR 52 HLA-DRB1 11 5.09×10–6 4.92 (2.52 to 9.97)
4-digit alleles are preferentially reported unless a 2-digit allele is significantly more associated. P values (uncorrected), OR and 95% CI were calculated in a regression including 
the most significantly associated independent variants. Associations reaching study-wide significance are reported (p<2.9×10–5).
HLA, human leucocyte antigen.
3). After stringent QC removing variants with low frequency 
(<0.01) and poor imputation accuracy (r2<0.8), our anal-
ysis included 509 classical HLA alleles and amino acids. In 
the primary analysis, adult-onset and juvenile-onset cases were 
combined and analysed together against matched healthy 
controls. Autoantibody associations reaching study-wide signifi-
cance of p<2.9×10–5 are reported in table 2.
The strongest HLA association was found with anti-Jo-1 auto-
antibodies and HLA-B*08:01 (p=2.28×10–53, OR=3.37, 95% 
CI 2.37 to 4.83). Conditioning on HLA-B*08:01 in a stepwise 
logistic regression model revealed an independent association 
with HLA-DRB1*03:01 (p=3.25×10–9, OR=3.09, 95% CI 
2.08 to 4.30). We analysed antisynthetase autoantibody posi-
tive patients as a group (n=381), and the strength of association 
became stronger (HLA-B*08:01, p=1.79×10–56, OR=3.14, 
95% CI 2.27 to 4.38 and HLA-DRB1*03:01, p=3.31×10–9, 
OR=2.73, 95% CI 1.96 to 3.80). We did not find associations 
with rarer aminoacyl-tRNA-synthetases individually, likely due 
to small sample sizes. However, in a small sample size of 23 
patients, only 30.4% of patients with anti-PL7 antibodies carried 
HLA-DRB1*03:01, compared with 79.2% of patients with anti-
Jo-1 autoantibodies, and 23% of healthy controls (online supple-
mentary table 4). This may suggest that not all antisynthetase 
autoantibodies have the same associations with 8.1 AH. The 
‘haplotype phased’ raw HLA genotypes for patients with rarer 
antisynthetase autoantibodies are included in online supplemen-
tary tables 5-10.
A strong HLA association was observed in patients 
with anti-TIF1 autoantibodies with the HLA-allele group 
DQB1*02 (p=2.34×10–10, OR=2.49, 95% CI 1.88 to 
3.31). Within this allele group, there were associations with 
HLA-DQB1*02:01 (p=1.69×10–5) and HLA-DQB1*02:02 
(p=1.04×10–4).
Associations with class II alleles of the 8.1 AH were observed 
for patients with anti-Jo-1, anti-PM/Scl and anti-cN1A. Anti-
HMGCR and anti-Mi-2 were the only autoantibodies tested that 
were associated with HLA alleles not forming part of the 8.1 
AH. Although the strong association with anti-HMGCR auto-
antibodies and HLA-DRB1*11 was confirmed in adult-onset 
patients, a stronger association was observed with the 4-digit 
allele HLA-DRB1*11:01 (p=3.22×10–7, OR=11.90, 95% CI 
4.72 to 31.85) before the allele was removed from the initial 
analysis due to low imputation accuracy (r2=0.75).
Using a more conservative threshold correcting for the 
number of antibodies analysed (p<2.4×10–6), the associa-
tion with HLA-DRB*11 and anti-HMGCR autoantibodies did 
not reach our significance threshold. There were no signifi-
cant associations with classical HLA alleles and anti-NXP2, 
anti-SRP, anti-MDA5 or anti-SAE autoantibodies.
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Table 3 The strongest amino acid associations in autoantibody subgroups of IIM
Autoantibody number of cases
Amino acid association
Gene Variant P value Or (95% CI)
Jo-1 332 HLA-DRB1 Position 74 Omnibus 3.47×10–64
  Alanine (ref)  
  Arginine 1.24×10--8 2.94 (2.03 to 4.26)
  Glutamine 0.02 0.59 (0.38 to 0.89)
  Leucine 6.21×10–5 2.78 (1.67 to 4.55)
  Glutamic acid 0.5 1.20 (0.70 to 1.96)
 HLA-B Position 9 Omnibus 7.03×10–11
  Tyrosine (ref)  
  Aspartic acid 2.10×10–10 3.33 (2.30 to 4.84)
  Histidine 0.77 0.96 (0.73 to 1.26)
TIF1 197 HLA-DQB1 Position 37 Omnibus 1.49×10–10
  Tyrosine (ref)  
  Isoleucine 2.34×10–10 2.49 (1.88 to 3.31)
PM/Scl 136 HLA-DRB1 Position 74 Omnibus 2.48×10–40
  Alanine (ref)  
  Arginine 5.06×10–25 18.37 (10.88 to 32.98)
  Glutamine 0.43 1.26 (0.70 to 2.21)
  Leucine
Glutamic acid
0.58
0.58
0.70 (0.17 to 2.32)
1.34 (0.44 to 3.56)
Mi-2 104 HLA-DRB1 Position 4 Omnibus 3.69×10–13
  Arginine (ref)  
  Glutamine 3.26×10–12 4.93 (3.17 to 7.79)
cN1A 64 HLA-DRB1 Position 74 Omnibus 6.15×10–14
  Alanine (ref)  
  Arginine 1.37×10–9 8.68 (4.43 to 18.1)
  Glutamine 0.02 0.17 (0.03 to 0.61)
  Leucine 0.05 3.31 (0.93 to 11.02)
  Glutamic acid 0.43 0.45 (0.03 to 2.30)
SRP 45 HLA-DRB1 Position 74 Omnibus 1.91×10–5
  Alanine (ref)  
  Arginine 9.47×10–4 3.51 (1.69 to 7.57)
  Glutamine 0.13 0.38 (0.08 to 1.18)
  Leucine 0.63 1.36 (0.32 to 4.34)
  Glutamic Acid 5.69×10–4 5.07 (2.05 to 13.17)
HMGCR 42 HLA-DRB1 Position 58 Omnibus 2.42×10–6
  Alanine (ref)  
  Glutamic acid 5.13×10–6 4.91 (2.52 to 9.97)
SAE 31 HLA-DQB1 Position 57 Omnibus 2.66×10–6
  Aspartic acid (ref)  
  Alanine 1.71×10–5 8.52 (3.42 to 24.47)
  Valine 0.41 1.61 (0.49 to 4.92)
  Serine 0.94 0.92 (0.04 to 7.66)
OR and 95% CI were calculated in a regression model including significant independent variants, using the most common amino acid in the population as the reference. 
Associations reaching study-wide significance are reported (p<2.9×10–5).
IIM, idiopathic inflammatory myopathies.
Amino acid positions may be more strongly associated than 
classical HLA alleles
SNP2HLA was used to impute amino acid positions. We 
employed a case-control study design in each autoantibody 
subgroup analysis, and autoantibodies with significant amino 
acid associations are reported in table 3.
The omnibus p value reports the significance of the amino 
acid position, and the effect sizes of the potential amino acids 
at this location were calculated in a regression model. The loca-
tion of associated amino acids within the 3D structure of HLA 
molecules are shown in online supplementary figure 1. For some 
autoantibodies, such as anti-Jo-1, anti-PM/Scl and anti-cN1A, 
amino acid associations were markedly stronger than the clas-
sical HLA associations reported in table 2. Regional association 
plots for autoantibodies with significant associations are shown 
in online supplementary figure 2A-H. Using a more conserva-
tive threshold correcting for the number of antibodies analysed 
(p<2.4×10–6), associations with amino acids and anti-SRP, anti-
HMGCR and anti-SAE autoantibodies did not reach our signif-
icance threshold.
For anti-Jo-1, anti-PM/Scl, anti-cN1A and anti-SRP auto-
antibodies, the strongest association was with position 74 of 
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Table 4 Differences in association at the HLA-DQB1*02 locus in 
adult-onset and juvenile-onset patients with anti-TIF1 autoantibodies
dQb1*02:01 dQb1*02:02
Adult-onset TIF1, n=91 P=0.06
OR=1.54 (0.97 to 2.44)
P=2.96×10–5
OR=3.31 (1.89–5.84)
Juvenile-onset TIF1, n=106 P=3.70×10–5
OR=2.47 (1.61 to 3.80)
P=0.13
OR=1.50 (0.87 to 2.51)
OR with 95% CI.
.
HLA-DRB1 (table 3). For anti-Jo-1, anti-PM/Scl and anti-
cN1A autoantibodies, an arginine at position 74 of HLA-DRB1 
conferred the strongest risk. In patients with anti-PM/Scl and 
anti-cN1A autoantibodies, an arginine conferred all of the risk at 
this position, whereas in patients with anti-Jo-1 autoantibodies 
there was also evidence of risk attributable to other amino acids.
Stepwise conditional analysis showed evidence of multiple 
independent effects in the HLA region with anti-Jo-1; posi-
tion 74 of HLA-DRB1 and position 9 of HLA-B. These were 
associated at a similar level of significance (p=3.47×10–64 vs 
p=5.25×10–64) and remained significant after conditioning on 
either position. Analysing antisynthetase autoantibody positive 
patients as a group increased the strength of association with 
these independent amino acid positions (HLA-DRB1 Position 
74, p=5.69×10–67 and HLA-B Position 9, p=8.63×10–11).
HLA alleles may differentiate adult-onset and juvenile-onset 
patients with anti-TIF1 autoantibodies
For autoantibodies that occur at high frequencies in both adult-
onset and juvenile-onset patients with IIM, the cohort was strat-
ified to investigate potential differences in HLA associations 
between these populations. Patients with anti-TIF1 autoanti-
bodies were stratified into adult-onset (n=91) and juvenile-onset 
(n=106) disease. Of these, all but six adult-onset patients were 
recorded as having DM. The association at the HLA-DQB1 
locus differed between adult-onset and juvenile-onset patients 
(table 4). In adult-onset IIM, the strongest 4-digit HLA asso-
ciation was with HLA-DQB1*02:02 (p=2.96×10–5, OR=3.31, 
95% CI 1.89 to 5.84). In contrast, in juvenile-onset patients, a 
strong association with HLA-DQB1*02:01 was observed, but the 
strongest association was with HLA-DRB1*03:01 (p=6.21×10–
6, OR=2.69, 95% CI 1.75 to 4.15), which is on the same haplo-
type as HLA-DQB1*02:01.
To ensure that this difference was not due to the effects of 
different methods of autoantibody detection, analysis was 
restricted to UK patients serotyped using IP in the same centre 
at the University of Bath. Nineteen additional juvenile-onset 
patients were included, recently genotyped through the Juvenile 
Dermatomyositis Cohort Biomarker Study and Repository. This 
subanalysis included UK adult-onset (n=40) and juvenile-onset 
patients (n=48) with anti-TIF1 autoantibodies. The strongest 
associations for juvenile-onset patients were with alleles of the 
8.1 AH, which were not significant in the adult-onset cohort. 
For example, HLA-DQB1*02:01 had a stronger association in 
the juvenile-onset cohort (p=0.004, OR=2.48, 95% CI 1.33 
to 4.61) in comparison to the adult-onset cohort (p=0.11, 
OR=1.69, 95% CI 0.87 to 3.20). Conversely, HLA-DQB1*02:02 
was more strongly associated in adult-onset (p=0.01, OR=2.38, 
95% CI 1.16 to 4.76) than in juvenile-onset disease (p=0.09, 
OR=1.85, 95% CI 0.89 to 3.64), thus replicating trends from 
the original cohort. However, due to the reduced sample size, 
these associations did not reach study-wide significance. These 
trends were also seen when restricting the analysis to US juve-
nile-onset patients with anti-TIF1 autoantibodies (n=70); the 
association with HLA-DQB1*02:01 (p=0.01, OR=2.05, 95% 
CI 1.18 to 3.54) was stronger than with HLA-DQB1*02:02 
(p=0.76, OR=0.89, 95% CI 0.40 to 1.81).
There were no significant classical HLA or amino acid asso-
ciations in either adult-onset or juvenile-onset patients with 
anti-NXP2 or anti-MDA5 autoantibodies. For anti-Jo-1, 
anti-PM/Scl, anti-Mi-2 and anti-cN1A, the numbers in the 
juvenile-onset cohorts were too small to reach our study-wide 
significance. However, for alleles associated in the total cohort, 
the trends for association were in the same direction in juve-
nile-onset IIM (online supplementary table 11).
dIsCussIOn
We used HLA imputation to find associations with IIM autoanti-
bodies and both classical HLA alleles and amino acid positions that 
may confer risk. By applying this novel approach, we report for 
the first genetic differences between adult-onset and juvenile-onset 
anti-TIF1-positive patients. There are independent associations of 
HLA-DRB1 and HLA-B for the development of anti-Jo-1 autoanti-
bodies, implicating multiple genetic features of the 8.1 AH. Amino 
acid imputation identified novel associations with autoantibodies 
that are stronger than the classical HLA allelic association, indi-
cating key positions within HLA molecules that may confer risk 
for various antibodies.
For certain autoantibodies, the strongest amino acid associations 
were at a similar level of significance as the strongest specific HLA 
association (online supplementary figure 2A-H). These amino 
acids may act as a proxy for the risk allele due to carriage on 
risk haplotypes. In other instances, amino acid associations were 
markedly more significant than any HLA allele. For example, in 
patients with anti-PM/Scl autoantibodies, amino acid position 74 
of HLA-DRB1 had a stronger association (p=2.48×10–40) than 
any allelic association (p=1.47×10–26). For patients with anti-Jo-1 
autoantibodies, forward stepwise conditional analysis suggested 
independent associations within the 8.1 AH of HLA-B*08:01 and 
HLA-DRB1*03:01. Other MSAs may have multiple independent 
associations within the HLA region that we were underpowered 
to detect, in line with other seropositive autoimmune diseases.17
Imputation of classical HLA alleles confirmed strong associ-
ations between alleles of the 8.1 AH and anti-Jo-1, anti-PM/Scl 
and anti-cN1A autoantibodies. Specific HLA alleles are thought to 
target particular autoantigens, resulting in a breakdown in immu-
nological tolerance to self-antigens. However, studies have shown 
that there are additional genetic features of the 8.1 AH that predis-
pose individuals to immune-mediated diseases, such as NF-kappaB 
and TNF-alpha polymorphisms,18 19 and gene copy number vari-
ants of complement genes.20 The association of alleles independent 
of the 8.1 AH with anti-Mi-2 and anti-HMGCR, as well as finding 
that some autoantibodies do not have strong HLA associations, 
suggests that not all patients with IIM share a common genetic 
risk. The 8.1 AH may be more critical for generation of a particular 
autoantibody repertoire rather than for the development of IIM. 
Environmental triggers including viruses, infections, UV radiation, 
drugs and additional genetic risk factors may contribute to disease 
heterogeneity.
The position of amino acids may give insight into whether these 
associations are functionally important. For example, amino acid 
position 74 faces inwards of the peptide binding groove in HLA 
DR molecules and may change the structure to accommodate 
autoantigenic peptides, whereas amino acid position 4 lies outside 
of the peptide binding groove (online supplementary figure 1). 
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An arginine at position 74 of HLA-DRB1 was the most strongly 
associated amino acid position in patients with anti-Jo-1, anti-PM/
Scl and anti-cN1A autoantibodies and has been implicated in 
other autoimmune diseases in Caucasian individuals.21 Arg-74 
almost exclusively resides on HLA-DRB1*03 alleles, which may 
explain the strong association with many IIM autoantibodies and 
HLA-DRB1*03:01. It will be interesting to examine whether risk 
alleles in other ethnic populations share the same amino acids as 
in Caucasian populations.22 Our method of analysis was unable to 
distinguish whether risk was attributable to amino acid motifs or to 
individual amino acid positions due to the high level of LD within 
these molecules. Previous studies have identified HLA-DRB1 motif 
9EYSTS13 as risk for IIM,23 and the HLA-DRB1 motif 70QKXXR74 
for patients with anti-Jo-1 and anti-PM/Scl autoantibodies.9 In 
both of these cases, however, the motifs are no stronger than the 
classical association with HLA-DRB1*03:01, or indeed an arginine 
at position 74 of HLA-DRB1.
We found evidence of different haplotypic associations for 
adult-onset and juvenile-onset patients with anti-TIF1 autoanti-
bodies. After stratifying by age, there was an association between 
anti-TIF1 autoantibodies and the 8.1 AH in juvenile-onset patients 
that was absent in adult-onset patients. Differences in association 
could be due to distinct aetiologies or to epitope spreading. An 
association of anti-TIF1 autoantibodies with cancer in adult-onset 
disease is not present in juvenile-onset disease.24 25 Cancer-associ-
ated myositis may develop as a paraneoplastic process, with neoan-
tigens in the cancer triggering autoimmunity in adult disease.26 In 
juvenile-onset patients with anti-TIF1 autoantibodies, however, 
an association with the 8.1 AH may suggest a different aetiology, 
where environmental risk factors such as infections,27 28 UV expo-
sure29 or others,30 may initiate disease. Differences in association 
with anti-HMGCR autoantibodies in adult-onset patients (HLA-
DRB1*11:01) and juvenile onset-patients (HLA*DRB1*07:01) 
have recently been described.13
There are some limitations with our study. Due to the nature 
of this large multicentre collection, not all patients were tested 
using gold standard IP. Alternatively, patients were included if they 
tested positive for an autoantibody by a commercially available 
line blot. Although concordance between these different methods 
has not been comprehensively studied, there is evidence that these 
assays are robust.31 32 A subanalysis of patients with anti-Jo-1 and 
anti-PM/Scl autoantibodies serotyped using EUROIMMUN line 
blots resulted in the same associations as those serotyped by IP 
(data not shown). Another limitation is the potential mischarac-
terisation of patients as antibody negative. Patients may have rare 
autoantibodies not currently included on commercially available 
line-blots, undiscovered antibodies not detectable in cell lines used 
for IP or low/negative titres of antibody during disease remission. 
Mischaracterising patients as antibody negative would result in a 
type-2 error and should not affect our primary findings. For these 
reasons, we did not compare antibody positive against antibody 
negative-patient groups.
In conclusion, these results confirm strong associations 
between HLA alleles and autoantibody specificities present in 
Caucasian patients with IIM. As well as strong associations with 
the 8.1 AH, we show that there are associations independent 
of this haplotype and that risk within this region may differ 
between adult-onset and juvenile-onset patients with anti-TIF1 
autoantibodies. As autoantibodies in myositis correlate with 
specific clinical features of disease, understanding the mecha-
nisms behind development of different autoantibodies should be 
a focus of ongoing research.
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